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ogen degradation products (FgDP). tHcy was significantly corre-Inflammation, not hyperhomocysteinemia, is related to oxida-
lated with plasma creatinine (r  0.29, P  0.018) and withtive stress and hemostatic and endothelial dysfunction in uremia.
serum folate (r  0.38, P  0.002). However, no significantBackground. Several cardiovascular risk factors are present
correlations were observed between tHcy and TBARS, AOPP,in patients with chronic renal failure (CRF), among which are
vWF:Ag, sICAM-1, sTM, TAT, F12, sTF, PAP, FnDP, andsystemic inflammation and hyperhomocysteinemia. Increased
oxidative stress, endothelial activation/dysfunction, and coagu- FgDP. Conversely, acute-phase proteins showed significant,
lation activation are considered integral components of the in- positive correlations with most markers of oxidative stress,
flammatory response, but have also been proposed as mediators endothelial dysfunction and hemostatic activation.
of plasma homocysteine (tHcy)-induced cell damage. Using Conclusions. Systemic inflammation, which is closely associ-
correlation analysis, we assessed the relative contributions of ated with augmented oxidative stress, endothelial cell dysfunc-
inflammation and hyperhomocysteinemia in the abnormal oxi- tion and hemostatic activation, emerges as a major cardiovascu-
dative stress, endothelial activation/dysfunction, and hemostasis lar risk factor in CRF. tHcy is unrelated to these events. Thus,
activation in patients with CRF. alternative mechanisms through which hyperhomocysteinemia
Methods. The relationships of inflammatory proteins and could predispose to vascular lesion and thrombotic events in
tHcy with plasma markers of these processes were studied in CRF needs to be investigated.
64 patients with CRF (serum creatinine 526  319 mol/L)
on conservative treatment, comparing the results with healthy
controls (N  15 to 40, depending on the measured variable)
Ischemic cardiovascular disease associated with accel-of similar sex and age.
Results. Patients had significant increases in inflammatory erated atherosclerosis is the most important cause of
cytokines (TNF- and IL-8) and acute-phase proteins (C-reac- death in patients at all stages of progressive kidney dis-
tive protein, fibrinogen and 1-antitrypsin). tHcy was increased
ease [1]. Hyperhomocysteinemia, an independent car-in 87.5% of patients (mean  27.1 mol/L, range 6.5 to 118).
diovascular risk marker [2], is present in 85 to 100% ofPatients had significant increases in (1) indices of oxidative
stress: TBARS (thiobarbituric acid-reactive species), a marker these patients in direct relation to the severity of renal
of lipid peroxidation and AOPP (advanced oxidation protein failure [3]; however, its role as a causal cardiovascular
products), a marker of protein oxidation; (2) endothelial cell risk factor is debated [4]. According to recent prospectivemarkers such as von Willebrand factor (vWF:Ag), soluble
studies, the ability of plasma homocysteine (tHcy) toICAM-1 and soluble thrombomodulin (sTM); (3) markers of
predict cardiovascular events or death in end-stage renalintravascular thrombin generation: thrombin-antithrombin com-
plexes (TAT) and prothrombin fragment F12 (PF12); and (4) disease is controversial, revealing either a graded in-
indices of activation of fibrinolysis: plasmin-antiplasmin com- crease in relative risk with the rise of tHcy [5] or a worse
plexes (PAP), fibrin degradation products (FnDP) and fibrin-
survival rate in patients with lower tHcy [6].
Mechanisms proposed for the vascular damage in-
duced by hyperhomocysteinemia are heterogeneous, in-Key words: hyperhomocysteinemia, cardiovascular disease, thrombo-
sis, vascular lesion, plasma homocysteine, uremia, ischemia. cluding impaired nitric oxide-dependent vasodilation,
endothelial dysfunction and injury, increased oxidative
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Table 1. Demographic characteristics of the patients with chronic preceding 30 days. They did not take vitamin supple-
renal failure
ments containing folic acid or vitamins B12, B6, or vitamin
Variable Value C from at least two months before the study. Forty
N 64 healthy subjects (mean age of 49  13 years, 20 women
Age years 5217 and 20 men) were studied in parallel with patients. Sam-
Women/men 31/33
ples from all these individuals served as normal controlsSerum creatinine lmol/L 526319
BUN mmol/L 21.48.0 for tHcy. As detailed in the Results section, for all other
Serum albumin g/L 346.0 variables, random samples from at least 15 of these 40
Total serum cholesterol mmol/L 4.891.65
healthy individuals served as controls. Patients gave writ-Proteinuria g/day 1.151.06
Hematocrit 0.300.06 ten consent to participate in the study, which was ap-
Renal biopsy 16/64 proved by the medical ethics committee of our institution.
Blood sampling and processing
Blood was collected from a forearm vein using a 19-
with chronic renal failure (CRF). In fact, the progression gauge butterfly needle after the patient had fasted for
of kidney failure is associated with impaired endothe- 10 to 12 hours. Two milliliters were used for measure-
lium-dependent vasodilation [8], elevated plasma mark- ments of serum creatinine, blood urea nitrogen (BUN),
ers of endothelium dysfunction [9], enhanced oxidative albumin, total cholesterol, folate and vitamin B12; an
stress [10, 11], and intravascular indices of hemostatic additional 2 mL were drawn in ethylenediaminetetraace-
activation [12, 13]. Whether these alterations in vivo are tic acid (EDTA). Aliquots were used to measure hema-
related to or partially dependent on the elevation of tHcy tocrit and blood platelet count, and the platelet-poor
is currently unknown. On the other hand, such processes plasma was frozen at 70C within 30 minutes after
are intrinsic constituents of systemic inflammation, a fre- blood collection and saved for tHcy determination. Nine
quent feature in these patients [14, 15] that is a cardiovas- milliliters were drawn in two vacuum tubes, each con-
cular risk factor [16, 17]. In this context, the links between taining 0.5 mL of sodium citrate (0.13 mol/L, 9/1 vol/
systemic inflammation with in vivo oxidative stress [18] vol), which were immediately placed in melting ice for
and with endothelial cell [19] and hemostatic activation 15 minutes, centrifuged for 15 minutes at 3200 	 g at
[20, 21] are well known. 4C, and the collected platelet-poor plasma aliquoted
Accordingly, the aim of this study was to measure and stored at70C until processed. These samples were
tHcy and plasma markers of inflammatory response and used for measurements of inflammatory cytokines, acute-
analyze their relationships with coexisting endothelial phase proteins, and plasma markers of endothelium dys-
dysfunction, oxidative stress, and hemostatic activation function/activation, of oxidative stress and of hemostasis
in patients with different degrees of CRF under conser- activation.
vative treatment.
Laboratory tests
Plasma creatinine was measured by kinetic Jaffe´METHODS
method (Autonalyzer Hitachi 917; Roche). Creatinine
Patients clearance was calculated using the Cockcroft-Gault for-
Sixty-four patients were enrolled in this study before mula [22]. Serum albumin was measured with bromocre-
initiating chronic maintenance hemodialysis or perito- sol green method (Autoanalyzer Hitachi 917; Roche).
neal dialysis. Demographic data of the patients are pre- Fasting tHcy in EDTA plasma was measured by high
sented in Table 1. This population had no nephrotic syn- pressure liquid chromatography (HPLC) with fluoro-
drome, diabetes mellitus, systemic vasculitis or lupus metric detection (Chromsystems, Mu¨nchen, Germany).
erythematosus, infections, or other diseases known to Folate and vitamin B12 in serum were determined by
be associated with clinical or laboratory perturbations ion capture and microparticle immunoassay, respectively
of hemostasis. The cause of chronic renal insufficiency (IMX Folate and AxSYM B12; Abbott Laboratory, Ab-
was hypertensive renal disease (2 patients), chronic bott Park, IL, USA).
glomerulopathies (15 patients), tubulointerstitial disease Markers of systemic inflammatory reaction included
(3 patients), autosomal-dominant polycystic kidney dis- plasma levels of inflammatory cytokines and acute-
ease (3 patients), other nephropathies (2 patients), and phase proteins: tumor necrosis factor- (TNF; Cromo-
unknown etiology at the time of the study (39 patients). genix, Sweden), by enzyme-linked immunosorbent assay
Blood pressure at the time of study was less than 180/ (ELISA), interleukin-8 (IL-8; R&D Systems, Minneapo-
100 mm Hg with the patient in a supine position. Patients lis, MN, USA) by ELISA, C-reactive protein (CRP) by
did not receive anticoagulants or antiplatelet drugs and competitive immunoassay with a sensitivity of 0.18 mg/L
[23, 24]; plasma fibrinogen by the Clauss technique ashad not been transfused with blood products during the
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Table 2. Plasma concentrations of total homocysteine, inflammatory cytokines and acute-phase proteins in patients with
chronic renal failure and healthy controls
Patients
Plasma concentrationa (N  64) Controls P b
Total homocysteine lmol/L 27.1 (6.5–118) 8.4 (5.0–18) (N40) 0.0001
TNF- pg/mL 36.4 (3.8–137) 19.9 (2.4–43) (N16) 0.001
IL-8 ng/mL 12.9 (0.07–106) 3.2 (0.23–14.6) (N24) 0.0014
C-reactive protein mg/L 45 (32–283) 3.6 (1.6–16) (N36) 0.0001
Fibrinogen g/L 4.31.4 2.24.7 (N16) 0.0001
1-antitrypsin mg/dL 14333 11020 (N16) 0.0001
a Values represent mean  1 SD for variables with normal distribution and mean and range for data not fitting a normal distribution
b Non-paired t test or Mann-Whitney U test
reported [25]; and 1-antitrypsin (1AT) by nephelometry RESULTS
(Beckmann Array; Beckmann, Fullerton, CA, USA). Table 2 shows the plasma concentrations of tHcy, in-
Plasma lipid peroxidation was evaluated by measuring flammatory cytokines, and acute phase proteins in pa-
thiobarbituric acid reactive species (TBARS) by a colori- tients and controls. Plasma tHcy was significantly higher
metric reaction [26]. Oxidation of plasma proteins was in uremic subjects. Only 8 out of 64 patients (12.5%) had
assessed by measuring advanced oxidation protein prod- tHcy values within the normal range according to their
ucts (AOPP) using a spectrophotometric assay [10]. sex (women, 7.7  1.6 mol/L; men, 9.2  2.6 mol/L).
Plasma markers of endothelium dysfunction/activation The mean serum folate concentration in patients with
included (1) von Willebrand factor (vWFAg), measured by CRF (11.7  5.9 nmol/L) was slightly below the lower
sandwich-type ELISA, using vW1 as capture monoclonal limit of the normal range of our laboratory (12 to 33
antibody (kindly provided by Dr. Robert R. Montgomery, nmol/L). Vitamin B12 level in patients (mean 359, range
Milwaukee, WI, USA) and a peroxidase-conjugated de- 126 to 1475 pmol/L) was within the normal range (164 to
tecting rabbit antibody (Dako Corp., Carpinteria, CA, 835 pmol/L). tHcy was positively correlated with plasma
USA); (2) soluble thrombomodulin (ELISA; American creatinine (r 0.29, p 0.018) and negatively correlated
Diagnostica, Greenwich, CT, USA); (3) soluble ICAM-1 with serum folate level (r0.38, p 0.002). The corre-
(ELISA; R&D Systems). lation index between tHcy and serum vitamin B12 (r 
Activation of hemostasis (coagulation/fibrinolysis) was 0.18) was not statistically significant. Plasma levels of
assessed by measuring plasma thrombin-antithrombin inflammatory cytokines and acute phase proteins were
complexes (TAT), prothrombin fragment F12 (PF12; significantly higher in patients than in controls.
ELISA; Behringwerke AG, Marburg, Germany), plas- Similarly, patients had increased plasma markers of
min-antiplasmin complexes (PAP; ELISA; Behringwerke oxidative stress, endothelial dysfunction and hemostatic
AG) and fibrin (FnDP) and fibrinogen (FgDP) degrada- activation, as shown in Table 3. Additionally, a matrix
tion products, measured by sandwich-type immunoassay of significant, positive associations among these indices
(Organon Teknika, Boxtel, The Netherlands), with results was observed. Plasma concentration of TAT complexes
expressed in ng fibrinogen equivalents/mL (ngFE/mL). was significantly correlated with other markers of hemo-
Further details on these measurements have been pub- static activation, such as F12 (P  0.003), PAP (P 
lished previously [12]. 0.003), FnDP and FgDP (P  0.0001). TAT also was
correlated with TBARS, a marker of lipid peroxidation
Statistical analysis (P 0.008), and with plasma vWFAg, a marker of endo-
Analyses were performed using SPSS Base 9.0 (SPSS thelium activation/dysfunction (P 0.006). TBARS and
AOPP, an index of protein oxidation, were significantlyInc., Chicago, IL, USA). Results are expressed as mean
1 SD or as mean and range of individual values, for data related to markers of endothelium dysfunction and he-
mostatic activation, that is, TBARS was positively corre-fitting or not fitting a normal distribution, respectively.
Association between two variables was calculated using lated with FnDP and FgDP (P  0.008 and 0.004) and
with sTM (P  0.02). Finally, significant correlationsthe Pearson correlation or Spearman rank correlation
coefficient, for data fitting or not fitting a normal distribu- between AOPP with PAP complexes (P  0.01) and
vWFAg (P  0.003) were observed.tion, respectively. A comparison between patients and
controls was performed by the unpaired Student t test Markers of oxidative stress, endothelial dysfunction,
and hemostatic activation were correlated with plasmaor Mann-Whitney U test for data with normal or non-
normal distribution, respectively. A significance level of creatinine, tHcy and acute phase proteins (Table 4). As
shown, plasma creatinine was statistically correlated with5% was used for all the statistical tests.
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Table 3. Plasma markers of oxidative stress, endothelial activation/dysfunction and hemostatic activation in patients with
chronic renal failure and healthy controls
Patients
Plasma concentration (N  64) Controls P
TBARS lmol/L 1.980.48 1.550.39 (N15) 0.009
AOPP mmol, eq. chloramine T 281 (45–915) 121 (14–414) (N25) 0.0001
von Willebrand factor % 18278 11646 (N40) 0.0001
Soluble thrombomodulin ng/mL 15.72.1 5.70.45 (N16) 0.0001
Soluble ICAM-1 ng/mL 301 (174–508) 233 (179–275) (N15) 0.0001
TAT lg/L 3.3 (0.94–14.2) 2.1 (0.84–4.7) (N30) 0.03
PF12 nmol/L 3.01.1 1.80.8 (N25) 0.0001
PAP lg/L 874 (146–2302) 475 (321–805) (N16) 0.0001
FnDP ngFE/mL 675 (118–3622) 173 (9–543) (N23) 0.0001
FgDP ngFE/mL 391 (20–5875) 89 (20–236) (N27) 0.0001
Abbreviations are: TBARS, thiobarbituric acid-reactive species; AOPP, advanced oxidation protein products; TAT, thrombin-antithrombin complex; PF12,
prothrombin fragment F12; PAP, plasmin-antiplasmin complex; FnDP, fibrin degradation products; FgDP, fibrinogen degradation products. Values represent mean
1 SD for variables with normal distribution and mean and range for data not fitting a normal distribution. The unpaired Student t test or Mann-Whitney test was
used for analyses.
Table 4. Correlations of plasma creatinine, total plasma homocysteine (tHcy) and acute-phase proteins with markers of oxidative stress,
endothelial activation/dysfunction, and hemostatic activation in patients with chronic renal failure
Plasma C-reactive
Variable creatinine tHcy protein Fibrinogen 1-antitrypsin
TBARS r0.33 r0.06 r0.21 r0.32 r0.37
P0.01 PNS PNS P0.01 P0.005
AOPP r0.04 r0.12 r0.28 r0.46 r0.11
PNS PNS P0.025 P0.0003 PNS
vWF r0.29 r0.06 r0.45 r0.56 r0.39
P0.02 PNS P0.0002 P0.0001 P0.004
sTM r0.79 r0.04 r0.33 r0.56 r0.35
P0.0001 PNS P0.01 P0.0001 P0.008
sICAM-1 r0.19 r0.19 r0.33 r0.21 r0.16
PNS PNS P0.01 PNS PNS
TAT r0.21 r0.08 r0.17 r0.32 r0.15
PNS PNS PNS P0.01 PNS
PF12 r0.03 r0.16 r0.15 r0.28 r0.14
PNS PNS PNS P0.03 PNS
PAP r0.21 r0.04 r0.45 r0.64 r0.32
PNS PNS P0.0002 P0.0001 P0.02
FnDP r0.32 r0.12 r0.35 r0.61 r0.37
P0.02 PNS P0.005 P0.0001 P0.005
FgDP r0.38 r0.03 r0.31 r0.57 r0.39
P0.001 PNS P0.014 P0.0001 P0.004
Pearson’s correlation or Spearman rank correlation were used for data fitting or not fitting a normal distribution, respectively. Abbreviations are in the footnote
of Table 3.
several markers of endothelial dysfunction, oxidative in patients with predialysis CRF are related to systemic
inflammation, but not to hyperhomocysteinemia.stress and hemostatic activation, denoting their depen-
Almost 90% of the patients with CRF had increaseddence on the severity of CRF. Inflammatory proteins
tHcy, which was significantly related to the severity ofwere significantly correlated with most markers of these
kidney insufficiency and to serum folate levels. Evenprocesses. Conversely, tHcy was not significantly corre-
though a recent article associated hyperhomocysteine-lated with any of them. Figure 1 illustrates this difference,
mia with vascular inflammation in a murine model [27],depicting the association of fibrinogen and tHcy with
no correlation was found between tHcy and plasma in-selected markers of endothelial dysfunction, oxidative
flammatory markers, suggesting that both are indepen-damage and hemostasis activation.
dent processes in patients with CRF. Several mechanismsNo statistical relationship between tHcy and inflam-
have been proposed to explain the tissue damage in-matory proteins was detected (data not shown).
duced by increased plasma levels of homocysteine. In
vitro studies show that auto-oxidation of homocysteine
DISCUSSION in plasma induces the generation of oxygen-derived mol-
This study essentially shows that indices of lipid perox- ecules, which have been linked to endothelial toxicity
idation, protein oxidative damage, endothelium activa- [28]. In addition, hyperhomocysteinemia inhibits gluta-
thione peroxidase, a critical enzyme responsible for inac-tion/dysfunction, and coagulation/fibrinolysis activation
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Fig. 1. Correlations of plasma fibrinogen con-
centration and plasma homocysteine (tHcy)
with selected markers of endothelial dysfunc-
tion (von Willebrand factor), oxidative stress
(advanced oxidation protein products) and he-
mostasis activation (plasmin-antiplasmin com-
plexes). The Pearson or Spearman rank correla-
tion was used for statistical analysis, depending
if the data fitted or did not fit a normal distri-
bution, respectively.
tivating reactive oxygen species and, furthermore, may reaction used in our study is less sensitive and specific
than HPLC-based methods [11], elevated plasma levelspotentiate peroxyl radical-mediated nitric oxide inactiva-
tion [29], with resultant endothelial dysfunction and in- of malondialdehyde in patients with CRF have been
found with both techniques. We did not detect any rela-jury. Homocysteine-induced endothelium damage also
may be explained by several other mechanisms, as shown tionship between these protein and lipid oxidative mark-
ers and tHcy. Accordingly, our study in plasma samplesin the in vitro systems, and these account for the transfor-
mation of its normal antithrombotic phenotype into a of patients with CRF does not support the concept that
hyperhomocysteinemia toxicity is mediated through aprothrombotic one [7]. Thrombin generation may be
facilitated through the tHcy-induced monocyte expres- mechanism involving oxidative damage [28]. In this con-
text, our results are more in line with recent reportssion of tissue factor, an intravascular initiator of coagula-
tion, by a mechanism independent of oxidative stress disputing the notion that an enhanced tHcy-induced oxi-
dant stress is a major contributor to atherothrombotic[30]. Taken together, these observations strongly suggest
that the enhanced oxidative stress, endothelial dysfunc- complications [31, 32].
While significant increases were found in plasma levelstion and hemostatic activation that are regularly ob-
served in uremic patients could have a close relationship of von Willebrand factor, sTM and sICAM-1, as markers
of endothelium activation/dysfunction, no statistical rela-with the elevated tHcy concentration in these patients.
However, as discussed later in this article, the results of tionship with tHcy was detected. Our study did not assess
the relationship between tHcy and endothelium-depen-our study do not support this hypothesis.
Abnormally high plasma indices of lipid peroxidation dent vasodilation, a topic raised by the observation that
monkeys with diet-induced moderate hyperhomocys-(TBARS) and oxidative protein damage (AOPP) in pa-
tients with predialysis CRF confirmed previous observa- teinemia showed an impaired response to the endothe-
lium-dependent vasodilators acetylcholine and adeno-tions [10, 11]. Even though the TBARS colorimetric
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sine diphosphate (ADP) [33]. However, more recent Patients with CRF show features compatible with
chronic, systemic inflammatory response [14, 15]. Thereports found that the reduction, or even normalization,
of tHcy with folic acid administration in patients with increased plasma levels of inflammatory cytokines and
acute phase proteins observed in predialysis patientspredialysis CRF or on peritoneal dialysis treatment was
not accompanied with an improvement in endothelium- confirm these observations and indicate that artificial
surfaces or dialytic procedures are not causally involveddependent arterial dilation [8, 34]. Taken together, these
in the inflammatory reaction. The significant interrela-results suggest that the endothelial dysfunction in pa-
tionships between inflammatory proteins and the major-tients with CRF is not a consequence of hyperhomocys-
ity of markers of oxidative damage, endothelial dysfunc-teinemia.
tion, and hemostatic activation suggest that the systemicThe increased plasma levels of plasma TAT complexes
inflammation of uremia is a common and unifying factorand PF12, denoting enhanced thrombin generation, con-
underlying these processes. The observed associationsfirmed previous findings [12, 25, 35, 36]. Both coagulation
can be explained on the basis that activation of inflam-activation [36] and hyperhomocysteinemia [3] are pres-
matory cells generate reactive oxygen species and in-ent, since early phases of kidney insufficiency and a
flammation is intimately associated with activation ofcausal role for hyperhomocysteinemia in clotting activa-
both endothelium [19] and hemostatic system [20]. Intion have been suggested by many in vitro studies [re-
CRF, the inflammatory response coexists with increasedviewed in 37]. In fact, homocysteine has been shown
oxidative stress [18, 41] and endothelial dysfunction [34,to change the normal antithrombotic phenotype of the
42, 43]. Also, activation of hemostasis is a common fea-endothelium: Among other effects, it inhibits prosta-
ture of uremia [12, 25, 38, 44], and its link with inflamma-cyclin synthesis, activates factor V, inhibits protein C
tion in this disease also has been reported [21, 45]. Inactivation, down-regulates thrombomodulin expression,
this context, CRF can be viewed as a clinical model ofinduces tissue factor expression, and suppresses the ex-
mild, protracted systemic inflammation that is intrinsi-pression of heparan sulphate. Furthermore, it was re-
cally associated with oxidative stress, endothelial dys-cently shown that homocysteine induces tissue factor
function and hemostatic activation, which are all impor-expression by peripheral blood monocytes [30]. To-
tant mediators of atherosclerosis and thrombotic events.gether, all of these changes would create a prothrombotic
Many studies show that the association between tHcyenvironment facilitating thrombin generation. However,
and cardiovascular disease is strong, although firm evi-our study revealed a lack of significant correlation be-
dence for a causal relationship is still lacking [46]. Ourtween tHcy and the indices of clotting activation, sug-
study did not address the role of increased tHcy as agesting that increased tHcy does not have a causal role
cardiovascular risk factor in CRF, and we cannot discardin the coagulation abnormalities. These findings are in
this possibility. However, our data conflict with the pre-line with those of Lentz et al, who observed that monkeys
vailing notion that homocysteine-mediated damage inwith diet-induced hyperhomocysteinemia had no detect-
CRF results from increased oxidative damage, endothe-able increase in systemic activation of the coagulation
lium dysfunction, coagulation activation or inhibition ofsystem [32]. Furthermore, the increases of PAP com-
the fibrinolytic process. Alternative mechanisms throughplexes, FnDP and FgDP, confirming previous studies [12,
which elevation of tHcy predisposes to vascular lesions25, 35, 38], reflect increased in vivo plasmin generation
and thrombotic events in CRF should be investigated.with fibrin and fibrinogen breakdown. These biochemical
Noteworthy, these mediators of cardiovascular diseasesigns of hyperfibrinolysis in CRF are also in conflict with
are associated with the inflammatory response, whoseexperimental observations indicating that pathogenic ef-
initial triggering event is still unknown. In this context,fects of homocysteine may be related to inhibition of
our observations add evidence to the theory that chronicthe fibrinolytic process. In fact, homocysteine has been
inflammation is a major determinant of the atherothrom-shown to block tissue plasminogen activator binding to
botic risk of patients with CRF.annexin II, its receptor on endothelial cells [39], and
physiological concentrations of homocysteine inhibit
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